
A set of chameleon-like immune cells could be contributing to severe asthma in some patients. Intermediate group 2 innate lymphoid cells (ILC2s) appear to be able to get around cutting-edge asthma treatments by transforming into another type of immune cell. Targeted biologic drugs have revolutionized the treatment of severe asthma driven by eosinophils, which are white blood cells linked to ILC2s, researchers noted in a recent study in the journal Science Translational Medicine. However, not all patients respond to these biologic drugs — and the fact that ILC2s can transform themselves could be a reason why, researchers said. Intermediate ILC2s share traits of both ILC2s and another type of immune cell called group 3 innate lymphoid cells, or ILC3s. ILC3s are tied to another type of white blood cell called neutrophils. An inhaler is less likely to calm an asthma attack involving eosinophils and neutrophils, researchers said. “When asthma is associated with both eosinophils and neutrophils cells, individuals are generally less responsive to treatment with glucocorticosteroids — which are the mainstay of treatment for severe asthma,” researcher Dr. Parameswaran Nair said in a news release. He’s chair in airway diseases at McMaster University in Hamilton, Ontario, Canada. Severe asthma that resists standard therapies is believed to affect up to 10% of people with asthma, researchers said in background notes. “The findings from this research pave… read on > read on >